Three unprofitable healthcare companies went public this past week, out of a potential eight IPOs. These included a large biotech targeting rare diseases, a medical device maker, and a synthetic DNA company. The group raised $390 million and averaged a...read more
Twist Bioscience, which manufactures synthetic genes and other DNA-based products, raised $70 million by offering 5 million shares at $14, the low end of the range of $14 to $16. Twist Bioscience plans to list on the Nasdaq under the symbol TWST. J.P. Morgan...read more
As many as 7 IPOs could raise about $450 million in the week ahead, including 6 healthcare deals. Don't expect all of them to get done. IPOs have sold off alongside the broader markets, while the VIX Volatility Index is in the "IPO postponement zone." read more
Twist Bioscience, which manufactures synthetic genes and other DNA-based products, announced terms for its IPO on Wednesday.
The San Francisco, CA-based company plans to raise $75 million by offering 5 million shares at a price range of $14 to $16. Insiders...read more
US IPO Weekly Recap: 3 healthcare IPOs trade flat
Three unprofitable healthcare companies went public this past week, out of a potential eight IPOs. These included a large biotech targeting rare diseases, a medical device maker, and a synthetic DNA company. The group raised $390 million and averaged a...read more
Twist Bioscience prices IPO at $14, the low end of the range
Twist Bioscience, which manufactures synthetic genes and other DNA-based products, raised $70 million by offering 5 million shares at $14, the low end of the range of $14 to $16. Twist Bioscience plans to list on the Nasdaq under the symbol TWST. J.P. Morgan...read more
US IPO Week Ahead: Micro-cap healthcare dominates week with up to 7 IPOs
As many as 7 IPOs could raise about $450 million in the week ahead, including 6 healthcare deals. Don't expect all of them to get done. IPOs have sold off alongside the broader markets, while the VIX Volatility Index is in the "IPO postponement zone."read more
Synthetic DNA manufacturer Twist Bioscience sets terms for $75 million IPO
Twist Bioscience, which manufactures synthetic genes and other DNA-based products, announced terms for its IPO on Wednesday. The San Francisco, CA-based company plans to raise $75 million by offering 5 million shares at a price range of $14 to $16. Insiders...read more